Top

European Journal of Nutrition

Published in:

Open Access 01-03-2020 | Insulins | Original Contribution

Moderate consumption of fermented alcoholic beverages diminishes diet-induced non-alcoholic fatty liver disease through mechanisms involving hepatic adiponectin signaling in mice

Authors: Finn Jung, Tino Lippmann, Annette Brandt, Cheng Jun Jin, Anna Janina Engstler, Anja Baumann

Published in: European Journal of Nutrition | Issue 2/2020

Abstract

Purpose

Results of some epidemiological studies suggest that moderate alcohol consumption may be associated with a decreased risk to develop NAFLD. Here, the effect of the consumption of moderate beer and diluted ethanol, respectively, on the development of NAFLD were assessed.

Methods

Female C57BL/6J mice were fed a control diet (C-D) or a diet rich in fructose, fat and cholesterol (FFC) enriched isocalorically and isoalcoholically with beer (FFC + B) or plain ethanol (FFC + E) (2.5 g ethanol/kg body weight/day) for 7 weeks. Liver damage was assessed by histology using NAFLD activity score. Markers of inflammation, insulin resistance and adiponectin signaling were measured at mRNA and protein levels. Using J774A.1 cells as a model of Kupffer cells, the effect of alcoholic beverages on adiponectin receptor 1 (Adipor1) was assessed.

Results

Hepatic triglyceride concentration, neutrophil granulocytes, iNOS protein concentrations and early signs of insulin resistance found in FFC-fed mice were significantly attenuated in FFC+ B-fed mice (P < 0.05 for all). These findings were associated with a super-induction of Adipor1 mRNA expression (+ ~ 18-fold compared to all other groups) and a decrease of markers of lipid peroxidation in liver tissue of FFC + B-fed mice when compared to FFC-fed animals. Similar differences were not found between FFC– and FFC+ E-fed mice. Expression of Adipor1 was also super-induced (7.5-fold) in J774A.1 cells treated with beer (equivalent to 2 mmol/L ethanol).

Conclusions

These data suggest that moderate intake of fermented alcoholic beverages such as beer at least partially attenuates NAFLD development through mechanisms associated with hepatic AdipoR1 expression.

Available only for authorised users

Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58(3):593–608. https://doi.org/10.1016/j.jhep.2012.12.005 CrossRefPubMed

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84. https://doi.org/10.1002/hep.28431 CrossRefPubMed

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15(1):11–20. https://doi.org/10.1038/nrgastro.2017.109 CrossRefPubMed

Lim HW, Bernstein DE (2018) Risk factors for the development of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including genetics. Clin Liver Dis 22(1):39–57. https://doi.org/10.1016/j.cld.2017.08.008 CrossRefPubMed

Collaborators GBDRF (2018) Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1923–1994. https://doi.org/10.1016/S0140-6736(18)32225-6 CrossRef

Hart CL, Morrison DS, Batty GD, Mitchell RJ, Davey Smith G (2010) Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 340:c1240. https://doi.org/10.1136/bmj.c1240 CrossRefPubMedPubMedCentral

Dunn W, Sanyal AJ, Brunt EM, Unalp-Arida A, Donohue M, McCullough AJ, Schwimmer JB (2012) Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 57(2):384–391. https://doi.org/10.1016/j.jhep.2012.03.024 CrossRefPubMedPubMedCentral

Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, Ikeda F, Shiratori Y, Yamamoto K (2011) Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther 33(3):378–388. https://doi.org/10.1111/j.1365-2036.2010.04520.x CrossRefPubMed

Patel PJ, Smith D, Connor JP, Horsfall LU, Hayward KL, Hossain F, Williams S, Johnson T, Stuart KA, Brown NN, Saad N, Clouston AD, Irvine KM, Russell AW, Valery PC, Powell EE (2017) Alcohol consumption in diabetic patients with nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol 2017:7927685. https://doi.org/10.1155/2017/7927685 CrossRefPubMedPubMedCentral

10.

Landmann M, Wagnerberger S, Kanuri G, Ziegenhardt D, Bergheim I (2015) Beer is less harmful for the liver than plain ethanol: studies in male mice using a binge-drinking model. Alcohol Alcohol 50(5):493–500. https://doi.org/10.1093/alcalc/agv048 CrossRefPubMed

11.

Pelletier S, Vaucher E, Aider R, Martin S, Perney P, Balmes JL, Nalpas B (2002) Wine consumption is not associated with a decreased risk of alcoholic cirrhosis in heavy drinkers. Alcohol Alcohol 37(6):618–621. https://doi.org/10.1093/alcalc/37.6.618 CrossRefPubMed

12.

Kerr WC, Fillmore KM, Marvy P (2000) Beverage-specific alcohol consumption and cirrhosis mortality in a group of English-speaking beer-drinking countries. Addiction 95(3):339–346CrossRefPubMed

13.

Hege M, Jung F, Sellmann C, Jin C, Ziegenhardt D, Hellerbrand C, Bergheim I (2018) An iso-alpha-acid-rich extract from hops (Humulus lupulus) attenuates acute alcohol-induced liver steatosis in mice. Nutrition 45:68–75. https://doi.org/10.1016/j.nut.2017.07.010 CrossRefPubMed

14.

Dorn C, Massinger S, Wuzik A, Heilmann J, Hellerbrand C (2013) Xanthohumol suppresses inflammatory response to warm ischemia-reperfusion induced liver injury. Exp Mol Pathol 94(1):10–16. https://doi.org/10.1016/j.yexmp.2012.05.003 CrossRefPubMed

15.

Dorn C, Weiss TS, Heilmann J, Hellerbrand C (2010) Xanthohumol, a prenylated chalcone derived from hops, inhibits proliferation, migration and interleukin-8 expression of hepatocellular carcinoma cells. Int J Oncol 36(2):435–441. https://doi.org/10.3892/ijo_00000517 CrossRefPubMed

16.

Spruss A, Henkel J, Kanuri G, Blank D, Puschel GP, Bischoff SC, Bergheim I (2012) Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response. Mol Med 18:1346–1355. https://doi.org/10.2119/molmed.2012.00223 CrossRefPubMedPubMedCentral

17.

Wagnerberger S, Fiederlein L, Kanuri G, Stahl C, Millonig G, Mueller S, Bischoff SC, Bergheim I (2013) Sex-specific differences in the development of acute alcohol-induced liver steatosis in mice. Alcohol Alcohol 48(6):648–656. https://doi.org/10.1093/alcalc/agt138 CrossRefPubMed

18.

Sellmann C, Jin CJ, Engstler AJ, De Bandt JP, Bergheim I (2017) Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD). Eur J Nutr 56(8):2519–2527. https://doi.org/10.1007/s00394-016-1287-9 CrossRefPubMed

19.

Sellmann C, Baumann A, Brandt A, Jin CJ, Nier A, Bergheim I (2017) Oral supplementation of glutamine attenuates the progression of nonalcoholic steatohepatitis in C57BL/6J Mice. J Nutr 147(11):2041–2049. https://doi.org/10.3945/jn.117.253815 CrossRefPubMed

20.

Rodriguez FD, Simonsson P, Alling C (1992) A method for maintaining constant ethanol concentrations in cell culture media. Alcohol Alcohol 27(3):309–313PubMed

21.

Kanuri G, Weber S, Volynets V, Spruss A, Bischoff SC, Bergheim I (2009) Cinnamon extract protects against acute alcohol-induced liver steatosis in mice. J Nutr 139(3):482–487. https://doi.org/10.3945/jn.108.100495 CrossRefPubMed

22.

Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226(1):497–509PubMed

23.

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research N (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313–1321. https://doi.org/10.1002/hep.20701 CrossRefPubMed

24.

Kanuri G, Landmann M, Priebs J, Spruss A, Loscher M, Ziegenhardt D, Rohl C, Degen C, Bergheim I (2016) Moderate alcohol consumption diminishes the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice. Eur J Nutr 55(3):1153–1164. https://doi.org/10.1007/s00394-015-0929-7 CrossRefPubMed

25.

Beulens JW, van Beers RM, Stolk RP, Schaafsma G, Hendriks HF (2006) The effect of moderate alcohol consumption on fat distribution and adipocytokines. Obesity (Silver Spring) 14(1):60–66. https://doi.org/10.1038/oby.2006.8 CrossRef

26.

Spruss A, Kanuri G, Stahl C, Bischoff SC, Bergheim I (2012) Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest 92(7):1020–1032. https://doi.org/10.1038/labinvest.2012.75 CrossRefPubMed

27.

Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391(6670):900–904. https://doi.org/10.1038/36116 CrossRefPubMed

28.

Qiao L, Shao J (2006) SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 281(52):39915–39924. https://doi.org/10.1074/jbc.M607215200 CrossRefPubMed

29.

Park PH, Sanz-Garcia C, Nagy LE (2015) Adiponectin as an anti-fibrotic and anti-inflammatory adipokine in the liver. Curr Pathobiol Rep 3(4):243–252. https://doi.org/10.1007/s40139-015-0094-y CrossRefPubMedPubMedCentral

30.

Luo N, Chung BH, Wang X, Klein RL, Tang CK, Garvey WT, Fu Y (2013) Enhanced adiponectin actions by overexpression of adiponectin receptor 1 in macrophages. Atherosclerosis 228(1):124–135. https://doi.org/10.1016/j.atherosclerosis.2013.02.026 CrossRefPubMedPubMedCentral

31.

Sellmann C, Degen C, Jin CJ, Nier A, Engstler AJ, Hasan Alkhatib D, De Bandt JP, Bergheim I (2017) Oral arginine supplementation protects female mice from the onset of non-alcoholic steatohepatitis. Amino Acids 49(7):1215–1225. https://doi.org/10.1007/s00726-017-2423-4 CrossRefPubMedPubMedCentral

32.

Vonghia L, Leggio L, Ferrulli A, Bertini M, Gasbarrini G, Addolorato G, Alcoholism Treatment Study G (2008) Acute alcohol intoxication. Eur J Intern Med 19(8):561–567. https://doi.org/10.1016/j.ejim.2007.06.033 CrossRefPubMed

33.

Cederbaum AI (2012) Alcohol metabolism. Clin Liver Dis 16(4):667–685. https://doi.org/10.1016/j.cld.2012.08.002 CrossRefPubMedPubMedCentral

34.

Portillo Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K (2014) High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2014-2739 CrossRefPubMed

35.

Manco M (2017) Insulin Resistance and NAFLD: a dangerous liaison beyond the genetics. Children (Basel). https://doi.org/10.3390/children4080074 CrossRef

36.

Miyake T, Kumagi T, Hirooka M, Furukawa S, Yoshida O, Koizumi M, Yamamoto S, Watanabe T, Yamamoto Y, Tokumoto Y, Takeshita E, Abe M, Kitai K, Matsuura B, Hiasa Y (2016) Low alcohol consumption increases the risk of impaired glucose tolerance in patients with non-alcoholic fatty liver disease. J Gastroenterol 51(11):1090–1100. https://doi.org/10.1007/s00535-016-1194-0 CrossRefPubMed

37.

Barrio-Lopez MT, Bes-Rastrollo M, Sayon-Orea C, Garcia-Lopez M, Fernandez-Montero A, Gea A, Martinez-Gonzalez MA (2013) Different types of alcoholic beverages and incidence of metabolic syndrome and its components in a Mediterranean cohort. Clin Nutr 32(5):797–804. https://doi.org/10.1016/j.clnu.2012.12.002 CrossRefPubMed

38.

Marques-Vidal P, Vollenweider P, Waeber G (2015) Alcohol consumption and incidence of type 2 diabetes. Results from the CoLaus study. Nutr Metab Cardiovasc Dis 25(1):75–84. https://doi.org/10.1016/j.numecd.2014.08.010 CrossRefPubMed

39.

Yokoyama H (2011) Beneficial effects of ethanol consumption on insulin resistance are only applicable to subjects without obesity or insulin resistance; drinking is not necessarily a remedy for metabolic syndrome. Int J Environ Res Public Health 8(7):3019–3031. https://doi.org/10.3390/ijerph8073019 CrossRefPubMedPubMedCentral

40.

Paulson QX, Hong J, Holcomb VB, Nunez NP (2010) Effects of body weight and alcohol consumption on insulin sensitivity. Nutr J 9:14. https://doi.org/10.1186/1475-2891-9-14 CrossRefPubMedPubMedCentral

41.

Konda VR, Desai A, Darland G, Grayson N, Bland JS (2014) KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes. PLoS One 9(1):e87848. https://doi.org/10.1371/journal.pone.0087848 CrossRefPubMedPubMedCentral

42.

Tripp ML, Darland G, Konda VR, Pacioretty LM, Chang JL, Bland JS, Babish JG (2012) Optimized mixture of hops rho iso-alpha acids-rich extract and acacia proanthocyanidins-rich extract reduces insulin resistance in 3T3-L1 adipocytes and improves glucose and insulin control in db/db mice. Nutr Res Pract 6(5):405–413. https://doi.org/10.4162/nrp.2012.6.5.405 CrossRefPubMedPubMedCentral

43.

Minich DM, Lerman RH, Darland G, Babish JG, Pacioretty LM, Bland JS, Tripp ML (2010) Hop and acacia phytochemicals decreased lipotoxicity in 3T3-L1 Adipocytes, db/db mice, and individuals with metabolic syndrome. J Nutr Metab. https://doi.org/10.1155/2010/467316 CrossRefPubMedPubMedCentral

44.

Imhof A, Plamper I, Maier S, Trischler G, Koenig W (2009) Effect of drinking on adiponectin in healthy men and women: a randomized intervention study of water, ethanol, red wine, and beer with or without alcohol. Diabetes Care 32(6):1101–1103. https://doi.org/10.2337/dc08-1723 CrossRefPubMedPubMedCentral

45.

Beulens JW, de Zoete EC, Kok FJ, Schaafsma G, Hendriks HF (2008) Effect of moderate alcohol consumption on adipokines and insulin sensitivity in lean and overweight men: a diet intervention study. Eur J Clin Nutr 62(9):1098–1105. https://doi.org/10.1038/sj.ejcn.1602821 CrossRefPubMed

46.

Pravdova E, Macho L, Fickova M (2009) Alcohol intake modifies leptin, adiponectin and resistin serum levels and their mRNA expressions in adipose tissue of rats. Endocr Regul 43(3):117–125. https://doi.org/10.4149/endo_2009_03_117 CrossRefPubMed

47.

Bell S, Britton A (2015) The role of alcohol consumption in regulating circulating levels of adiponectin: a prospective cohort study. J Clin Endocrinol Metab 100(7):2763–2768. https://doi.org/10.1210/jc.2015-1845 CrossRefPubMedPubMedCentral

48.

Jung SK, Kim MK, Shin J, Choi BY (2013) A cross-sectional analysis of the relationship between daily alcohol consumption and serum adiponectin levels among adults aged 40 years or more in a rural area of Korea. Eur J Clin Nutr 67(8):841–847. https://doi.org/10.1038/ejcn.2013.74 CrossRefPubMed

49.

Nishise Y, Saito T, Makino N, Okumoto K, Ito JI, Watanabe H, Saito K, Togashi H, Ikeda C, Kubota I, Daimon M, Kato T, Fukao A, Kawata S (2010) Relationship between alcohol consumption and serum adiponectin levels: the Takahata study—a cross-sectional study of a healthy Japanese population. J Clin Endocrinol Metab 95(8):3828–3835. https://doi.org/10.1210/jc.2009-1862 CrossRefPubMed

50.

Maeda S, Mure K, Mugitani K, Watanabe Y, Iwane M, Mohara O, Takeshita T (2014) Roles of the ALDH2 and ADH1B genotypes on the association between alcohol intake and serum adiponectin levels among Japanese male workers. Alcohol Clin Exp Res 38(6):1559–1566. https://doi.org/10.1111/acer.12406 CrossRefPubMed

51.

Li H, Borinskaya S, Yoshimura K, Kal’ina N, Marusin A, Stepanov VA, Qin Z, Khaliq S, Lee MY, Yang Y, Mohyuddin A, Gurwitz D, Mehdi SQ, Rogaev E, Jin L, Yankovsky NK, Kidd JR, Kidd KK (2009) Refined geographic distribution of the oriental ALDH2*504Lys (nee 487Lys) variant. Ann Hum Genet 73(Pt 3):335–345. https://doi.org/10.1111/j.1469-1809.2009.00517.x CrossRefPubMedPubMedCentral

52.

Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52(7):1655–1663. https://doi.org/10.2337/diabetes.52.7.1655 CrossRefPubMed

53.

Hino K, Nagata H (2012) Screening for adiponectin secretion regulators. Vitam Horm 90:125–141. https://doi.org/10.1016/B978-0-12-398313-8.00005-1 CrossRefPubMed

54.

Ghoshal K, Bhattacharyya M (2015) Adiponectin: probe of the molecular paradigm associating diabetes and obesity. World J Diabetes 6(1):151–166. https://doi.org/10.4239/wjd.v6.i1.151 CrossRefPubMedPubMedCentral

55.

Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13(3):332–339. https://doi.org/10.1038/nm1557 CrossRefPubMed

56.

Gerhauser C (2005) Beer constituents as potential cancer chemopreventive agents. Eur J Cancer 41(13):1941–1954. https://doi.org/10.1016/j.ejca.2005.04.012 CrossRefPubMed

57.

Dorn C, Kraus B, Motyl M, Weiss TS, Gehrig M, Scholmerich J, Heilmann J, Hellerbrand C (2010) Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. Mol Nutr Food Res 54(Suppl 2):S205–S213. https://doi.org/10.1002/mnfr.200900314 CrossRefPubMed

Title: Moderate consumption of fermented alcoholic beverages diminishes diet-induced non-alcoholic fatty liver disease through mechanisms involving hepatic adiponectin signaling in mice
Authors: Finn Jung
Tino Lippmann
Annette Brandt
Cheng Jun Jin
Anna Janina Engstler
Anja Baumann
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Keywords: Insulins
Fatty Liver
Insulins
Published in: European Journal of Nutrition / Issue 2/2020
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-019-01945-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Moderate consumption of fermented alcoholic beverages diminishes diet-induced non-alcoholic fatty liver disease through mechanisms involving hepatic adiponectin signaling in mice

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Correction to: Exploring the association between whole blood Omega-3 Index, DHA, EPA, DPA, AA and n-6 DPA, and depression and self-esteem in adolescents of lower general secondary education

Dietary fibre intake and the risk of diverticular disease: a systematic review and meta-analysis of prospective studies

Targeting endothelial-to-mesenchymal transition: the protective role of hydroxytyrosol sulfate metabolite

Diet quality index for Brazilian adolescents: the ERICA study

Identification of potential human urinary biomarkers for tomato juice intake by mass spectrometry-based metabolomics

Association of free sugar intake with blood pressure and obesity measures in Australian adults

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page